Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Polpharma SA

FDA Reviews Natalizumab For Sandoz And Polpharma

Sandoz and Polpharma have quickly followed news of a European natalizumab filing with confirmation that the proposed biosimilar version of Tysabri has also been accepted for review by the US Food and Drug Administration.

Biosimilars Regulation

Polpharma Celebrates Being First With Natalizumab In Europe

Polpharma Biologics has claimed the first biosimilar natalizumab filing in Europe, after the European Medicines Agency accepted the firm’s marketing authorization application for review.

Biosimilars Europe

Formycon Strengthens Biosimilars Portfolio With Athos Assets

Formycon and Athos have merged aspects of their biosimilar development activities as part of a long-term strategic partnership.

M & A Deals

Three EU Tecfidera Generics Recommended As Biogen Battles For Exclusivity

Following a years-long back-and-forth to establish exclusivity protection for its Tecfidera multiple-sclerosis treatment in Europe, Biogen has ultimately seen the CHMP recommend three generic versions to receive pan-European marketing authorization.

Approvals Generic Drugs
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Polpharma Biologics
UsernamePublicRestriction

Register